Shoulder Innovations (SI) Financial Research Hub

Shoulder Innovations (SI) demonstrated robust financial performance in 1Q26, reporting revenue of $16.7 million which significantly exceeded consensus expectations. This growth was primarily fueled by a strategic expansion of the surgeon pipeline, with new surgeon additions doubling year-over-year within the sales funnel. Further supporting the top-line beat was a notable 9% increase in Average Selling Prices (ASP), indicating strong pricing power for its orthopedic solutions. In response to these results, Goldman Sachs revised its 2026 revenue forecast upward to $67.6 million and raised the 12-month price target to $20.00. Despite broader sector headwinds currently impacting small-to-mid cap MedTech companies, SI continues to outperform and capture market share. The company is operating within a healthy shoulder market characterized by high-single-digit growth, providing a favorable backdrop for continued expansion. Overall, the latest quarterly data reinforces the thesis that SI is successfully scaling through both product pricing and aggressive clinician adoption.